Epigral Limited has posted a robust start to FY27, reporting a 25% year-on-year rise in net profit while unveiling a Rs. 600-crore expansion that will take the company into the high-growth epoxy resin and specialty chemicals market.

 

The integrated chemicals manufacturer reported a profit after tax (PAT) of Rs. 99 crore for the quarter ended June 30, 2026, up from Rs. 79 crore a year earlier. Revenue rose 15% year-on-year to Rs. 709 crore, compared with Rs. 615 crore in the corresponding quarter of FY26.

 

In a major strategic move, the company's board approved the establishment of an Epoxy Resin & Formulations plant with an annual production capacity of 1,25,000 tonnes, along with a Multi-Purpose Plant (MPP). The projects, involving a combined investment of approximately Rs. 600 crore, are expected to be commissioned in the second half of FY28.

 

The expansion marks Epigral's entry into advanced materials and specialty chemicals through forward integration, targeting growing demand from sectors including construction, renewable energy, automotive, electronics, infrastructure, marine, aerospace, industrial flooring and semiconductors.

 

Epoxy resin is a key material used in high-performance applications such as wind turbine blades, fibre-reinforced polymers, tile adhesives, industrial coatings, chemical storage systems, electrical insulation, marine structures and automotive components. 

 

Demand in India continues to strengthen, driven by infrastructure development, manufacturing growth, renewable energy investments and the increasing use of advanced materials.

 

The new business is expected to benefit from Epigral's integrated manufacturing operations at Dahej, where the company already produces key raw materials, including Epichlorohydrin (ECH) and caustic soda. More than half of the raw material requirement for the epoxy resin project will be met internally, strengthening operational efficiencies and cost competitiveness.

 

Alongside the epoxy resin venture, Epigral will establish a Multi-Purpose Plant to manufacture downstream products from the Epichlorohydrin and Chlorotoluenes value chains. The facility will cater to rising domestic demand for pharmaceutical and agrochemical intermediates as well as water treatment chemicals.

 

As part of its phased rollout, the company is also setting up a pilot plant for the Epoxy Resin & Formulations and MPP businesses. Scheduled to become operational in Q2FY27, the facility will support product validation, process optimisation and customer approvals before commercial production begins.

 

Commenting on the results and development, Maulik Patel, Chairman and Managing Director, Epigral Limited, said: “Epigral delivered steady growth in Q1FY27 despite severe macroeconomic volatility driven by geopolitical tensions in West Asia. 

 

"The quarter was marked by fluctuations in raw material and finished goods prices, alongside elevated freight costs and shipment delays. Leveraging its diversified product mix, Epigral successfully navigated these headwinds to achieve 15% revenue growth and an EBITDA margin of 25%."

 

He added: "While geopolitical challenges persist, operating conditions have stabilized. Backed by India’s strong economic growth trajectory, management maintains a positive outlook. 

 

"To drive future diversified growth, the Board approved strategic investments in a new Epoxy Resin & Formulations plant and a Multi-Purpose Plant (MPP). Both expansions will enhance efficiency within Epigral’s integrated manufacturing complex by utilizing internal raw materials. Specifically, the Epoxy Resin plant will consume ECH and Caustic Soda, while the MPP will be downstream of Epichlorohydrin and Chlorotoluenes Value Chain.

 

"The Epoxy Resin plant will cater to domestic and global demand across the renewable energy, infrastructure, electronics, automotive, and industrial sectors. Concurrently, the MPP will meet rising domestic demand for pharmaceutical and agrochemical intermediates and water treatment chemicals."